Can finasteride lower blood pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Finasteride Lower Blood Pressure?

No, finasteride does not lower blood pressure in humans and is not indicated for hypertension management. The major hypertension guidelines do not list finasteride among blood pressure-lowering medications, and its mechanism of action—inhibiting 5α-reductase to reduce dihydrotestosterone—does not target cardiovascular pathways involved in blood pressure regulation 1.

Evidence from Hypertension Guidelines

  • The 2003 JNC 7 guidelines comprehensively list all classes of antihypertensive medications (thiazide diuretics, ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, alpha-blockers) but do not include 5α-reductase inhibitors like finasteride 1.

  • The 2024 ESC hypertension guidelines similarly catalog established and emerging blood pressure-lowering therapies—including SGLT2 inhibitors, GLP-1 agonists, and novel aldosterone synthase inhibitors—yet make no mention of finasteride or any 5α-reductase inhibitor for hypertension treatment 1.

Finasteride's Actual Mechanism and Effects

  • Finasteride works by inhibiting the 5α-reductase type II enzyme, which converts testosterone to dihydrotestosterone (DHT), thereby reducing prostatic DHT by approximately 70% and causing a 15–25% reduction in prostate volume within 6 months 1, 2.

  • The drug's documented effects are confined to the prostate and include improved urinary symptom scores (average 3-point improvement on AUA/IPSS), reduced risk of acute urinary retention (67% reduction), and decreased need for BPH-related surgery (64% reduction) 1, 2, 3.

  • Finasteride's adverse effects are primarily sexual (decreased libido in 6.4%, ejaculatory dysfunction in 3.7% during the first year) and do not include cardiovascular effects such as hypotension or changes in blood pressure 1, 2.

Animal Research Does Not Translate to Human Blood Pressure Effects

  • One rat study found that finasteride decreased prostatic blood flow after 7 days of treatment, with no significant changes in systemic blood pressure or kidney blood flow 4.

  • This finding reflects local vascular changes within the prostate gland itself—not systemic blood pressure reduction—and has no clinical relevance to human hypertension management 4.

Cardiovascular Safety in Heart Failure

  • The European Society of Cardiology guidelines confirm that finasteride has no direct cardiovascular effects and does not interfere with cornerstone heart failure medications (ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) 5.

  • A 2019 retrospective study in heart failure patients found that finasteride was associated with reduced left ventricular hypertrophy (interventricular septal thickness 13.3 mm control vs. 12.6 mm finasteride, p=0.029), but this reflects anti-androgenic effects on cardiac remodeling rather than blood pressure lowering 6.

Common Pitfall to Avoid

  • Do not confuse alpha-blockers (e.g., doxazosin, terazosin) with 5α-reductase inhibitors (finasteride, dutasteride). Alpha-blockers used for BPH do lower blood pressure and can cause orthostatic hypotension, but finasteride does not share this property 1, 5, 3.

  • Patients with both hypertension and BPH require separate antihypertensive therapy; finasteride alone will not control blood pressure 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Finasteride Therapy for Benign Prostatic Hyperplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Finasteride for benign prostatic hyperplasia.

The Cochrane database of systematic reviews, 2010

Guideline

Treatment Options for Benign Prostatic Hyperplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Does finasteride (a 5-alpha-reductase inhibitor) lower blood pressure (BP)?
What is the best course of action for a 92-year-old male with a history of Gleason-7 prostate cancer (Prostate Cancer) and low-grade superficial bladder transitional cell carcinoma (TCC), currently experiencing gross hematuria, with a Prostate-Specific Antigen (PSA) level of 1.09, and taking finasteride (Proscar) and tamsulosin (Flomax) for Benign Prostatic Hyperplasia (BPH)?
What is the appropriate management for a 97-year-old male with Benign Prostatic Hyperplasia (BPH), bilateral simple renal cysts, and a slightly elevated Prostate-Specific Antigen (PSA) level of 10, currently treated with doxazosin (Cardura) and finasteride (Proscar)?
A middle-aged man with BPH (Benign Prostatic Hyperplasia) symptoms and a smooth, symmetrically enlarged prostate experiences improved urinary symptoms and decreased prostate volume after starting a new medication, which medication is most likely responsible for the decreased prostate volume?
How to manage a 90-year-old male with BPH, nephrolithiasis, and bilateral renal cysts, on finasteride (5-alpha-reductase inhibitor) and tamsulosin (alpha-blocker)?
Which baseline and follow‑up laboratory tests should be ordered after starting perindopril 4 mg and amlodipine 5 mg daily in an adult with severe hypertension?
What is the appropriate treatment for Group A streptococcal pharyngitis in a pregnant woman?
What is the recommended rifampicin dose, frequency, and treatment duration for an adult with a soft‑tissue infection (e.g., prosthetic joint infection), including weight‑based dosing and adjustments for hepatic impairment?
What is the appropriate dosing regimen of subcutaneous vitamin B12 (cobalamin) 3000 µg for a patient with a serum vitamin B12 level of 159 pg/mL?
What other diseases can present with both chronic constipation and hypothyroidism in a patient whose constipation began before starting amlodipine?
What is the optimal pharmacologic treatment plan for Huntington's chorea, including first‑line VMAT2 inhibitors, dosing, and second‑line options?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.